49 completed, 12 terminated, 7 active not recruiting, 6 recruiting. 83 Phase 2, 12 Phase 1, 1 Phase 3.
Follow nilotinib: new trials by email Literature Review of nilotinib trials Research Report on nilotinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML Asciminib add-on, Imatinib, Dasatinib - Ph+ Acute Lymphoblastic Leukemia (Ph+ALL), Blastic Transformation of Chronic Myeloid Leukemia | Phase 2 | Not yet recruiting | The University of Hong Kong | 45 | 2026-03-30 | 2026-03-25 |
| PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML Asciminib, Nilotinib - CML, Chronic Phase, Chronic Myeloid Leukemia, Chronic Phase | Phase 2 | Recruiting | Gruppo Italiano Malattie EMatologiche dell'Adulto | 160 | 2025-06-26 | 2025-07-08 |
| Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 40 | 2023-07-14 | 2026-08-04 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial Alpelisib, Binimetinib, Biopsy Procedure - Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 2900 | 2023-04-07 | 2026-11-12 |
| Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis Paclitaxel, Nilotinib, ECG - Gynecologic Cancer, Gynecologic Neoplasms | Phase 2 | Completed | National Cancer Institute (NCI) | 21 | 2022-10-13 | 2026-06-25 |
| Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation Asciminib 40 MG, Asciminib 40 MG Twice Daily, Asciminib 80 MG daily - Chronic Phase Chronic Myelogenous Leukemia | Phase 2 | Recruiting | Medical College of Wisconsin | 51 | 2021-11-11 | 2026-08-25 |
| KRT-232 and TKI Study in Chronic Myeloid Leukemia KRT-232, Dasatinib, Nilotinib - Chronic Myeloid Leukemia | Phase 1 / Phase 2 | Unknown | Kartos Therapeutics, Inc. | 109 | 2021-05-07 | 2022-03-21 |
| Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal, Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation - Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission | Phase 2 | Active not recruiting | Baylor College of Medicine | 17 | 2020-12-22 | 2026-05-04 |
| Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Eicosapentaenoic Acid, Tyrosine kinase inhibitor - Chronic Myeloid Leukemia, Chronic Phase | Phase 1 / Phase 2 | Terminated | Milton S. Hershey Medical Center | 1 | 2020-09-14 | 2022-07-01 |
| Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel Nilotinib and Paclitaxel - Neoplasms | Phase 2 | Recruiting | National Cancer Institute (NCI) | 82 | 2020-08-24 | 2026-11-09 |
| Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid Leukemia Imatinib withdrawal, Dasatinib, Nilotinib - Chronic Myeloid Leukemia, Chronic Phase, Withdrawal;Drug | Phase 2 | Active not recruiting | Masaryk University | 150 | 2020-06-16 | 2024-11-26 |
| A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib) Imatinib, Nilotinib, Dasatinib - Chronic Myeloid Leukemia, Chronic Myeloid Leukemia in Remission | Phase 2 | Unknown | National Research Center for Hematology, Russia | 100 | 2020-01-15 | 2020-10-08 |
| A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase HQP1351, Hydroxyurea or Interferon-based therapy, Homoharringtonine - Chronic Myeloid Leukemia, Chronic Phase | Phase 2 | Completed | Ascentage Pharma Group Inc. | 144 | 2019-10-21 | 2025-03-03 |
| Frontline Asciminib Combination in Chronic Phase CML Imatinib, Nilotinib 300 mg, Dasatinib - Chronic Myeloid Leukemia | Phase 2 | Active not recruiting | University of Jena | 125 | 2019-08-19 | 2026-08-18 |
| Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy Bodies Placebo oral capsule, Nilotinib Oral Capsule - Dementia With Lewy Bodies | Phase 2 | Completed | Georgetown University | 43 | 2019-07-01 | 2026-06-12 |
| Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease Dasatinib, Imatinib Mesylate, Laboratory Biomarker Analysis - Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Minimal Residual Disease | Phase 2 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 40 | 2019-06-26 | 2026-09-15 |
| A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia Nilotinib, Asciminib - Chronic Myeloid Leukemia | Phase 2 | Terminated | Novartis Pharmaceuticals | 135 | 2019-03-22 | 2026-07-13 |
| Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response. Asciminib add-on, Imatinib, Nilotinib - CML, Chronic Myelogenous Leukemia | Phase 2 | Completed | Novartis Pharmaceuticals | 104 | 2018-11-22 | 2026-04-21 |
| Effect of Nilotinib in Cerebellar Ataxia Patients Nilotinib - Ataxia, Cerebellar, Ataxia, Progressive | Phase 2 | Completed | Seoul National University Hospital | 70 | 2018-11-19 | 2021-09-29 |
| Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia Bosutinib, Dasatinib, Laboratory Biomarker Analysis - Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Phase 2 | Active not recruiting | SWOG Cancer Research Network | 81 | 2018-10-24 | 2025-12-18 |
Showing 20 of 83. Sign in to see all of them.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (39) · Leukemia, Myeloid, Chronic-Phase (15) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (9) · Leukemia (7) · Gastrointestinal Stromal Tumors (6) · Neoplasm Metastasis (5) · Blast Crisis (4) · Leukemia, Myeloid, Acute (3) · Melanoma (3) · Neoplasms (3) · Hematologic Diseases (2) · Leukemia, Myeloid, Accelerated Phase (2) · Ovarian Neoplasms (2) · Recurrence (2) · Synovitis, Pigmented Villonodular (2)
Novartis Pharmaceuticals (18) · Gruppo Italiano Malattie EMatologiche dell'Adulto (4) · National Cancer Institute (NCI) (4) · University Health Network, Toronto (3) · Centre Leon Berard (2) · Fox Chase Cancer Center (2) · Fred Hutchinson Cancer Center (2) · Georgetown University (2) · M.D. Anderson Cancer Center (2) · Mayo Clinic (2) · Medical College of Wisconsin (2) · Amsterdam UMC, location VUmc (1) · Andrew J. Wagner, MD, PhD (1) · Ascentage Pharma Group Inc. (1) · Assistance Publique - Hôpitaux de Paris (1)
United States (37) · France (14) · Italy (13) · Germany (11) · Spain (11) · Canada (9) · Netherlands (9) · South Korea (9) · United Kingdom (9) · Japan (7) · Poland (6) · Belgium (5) · Denmark (5) · Israel (5) · Russia (5)
Ehab Atallah, MD (2) · Fernando L Pagan, MD (2) · Margaret von Mehren, MD (2) · Abhijit Guha (1) · Alice P Chen, M.D. (1) · Amer Zeidan (1) · Andrew Grigg, MBBS, MD, FRACP, FRCPA (1) · Andrew J. Wagner, MD, PhD (1) · Andrew M Blakely, M.D. (1) · Anna Turkina, Professor (1) · Anne Hansen Ree, Prof. MD PhD (1) · Aref Al-Kali (1) · Aref Al-Kali, M.D. (1) · Arnon Nagler, MD (1)
PMID 17715389, PMID 25361995, PMID 16775235, PMID 18048643, PMID 19822896, PMID 21098399, PMID 21456006, PMID 21478667, PMID 21508120, PMID 23065514, PMID 23547655, PMID 23620574, PMID 23666528, PMID 24057647, PMID 25387866, PMID 25695690, PMID 26002753, PMID 26113419, PMID 26283632, PMID 26687426, PMID 27434297, PMID 28042454, PMID 28298564, PMID 28327988, PMID 28566209, PMID 28601294, PMID 28835440, PMID 29459949, PMID 29486663, PMID 29571946, PMID 29609532, PMID 29996726, PMID 30026110, PMID 30885996, PMID 31201085, PMID 31511239, PMID 31841599, PMID 32208873, PMID 32499241, PMID 33180106, PMID 33513367, PMID 34309636, PMID 34786477, PMID 35086719, PMID 35598186, PMID 35932628, PMID 35943168, PMID 35982483, PMID 36624161, PMID 36870947
U10CA180820 (3), 2009 (2), P30CA015704 (2), 2015 (1), 2018 (1), P01CA018029 (1), P01CA078902 (1), P30CA015083 (1), U10CA180888 (1)